MiNK Therapeutics

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MiNK Therapeutics reports positive Q4 results, eyes growth opportunities

MiNK Therapeutics demonstrated strong performance in Q4 2022, with positive Phase I results for agenT-797 and advancements in iNKT cell therapy.
While facing challenges in development timelines and financial stability, MiNK's unique mechanisms of action in cancer treatment position it well for future growth.
Opportunities lie in financing prospects, upcoming presentations, collaborations, and continued innovation in iNKT cell therapy for MiNK to capitalize on.

MiNK Therapeutics reports promising Q1 results, focuses on innovative cancer therapies

MiNK Therapeutics showcased promising clinical data on agenT-797 in solid tumor cancers, emphasizing its potential efficacy and safety profile.
The company's strategic focus on iNKT cell therapies and the MiNK-215 program highlights innovative approaches to addressing immune suppression mechanisms in tumors.
While facing challenges in dose optimization and program prioritization, MiNK Therapeutics has opportunities to further advance its pipeline and explore novel cancer treatment avenues.
Analyst inquiries into expansion studies and development strategies indicate a growing interest in MiNK's innovative therapies and potential for future growth.

MiNK Therapeutics reports promising Q3 results amidst financial challenges

MiNK Therapeutics showcased financial prudence and promising clinical outcomes with AgenT-797, while facing challenges in financial sustainability and treatment optimization.
The company's strengths lie in unique immune activation, diversified research programs, and the therapeutic potential of iNKT cells in challenging cancer environments.
Opportunities for MiNK Therapeutics include advancing clinical trials, exploring new treatment avenues, and leveraging partnerships for market expansion and therapeutic advancements.

MiNK Therapeutics advances iNKT cell programs with promising results

MiNK Therapeutics showcased progress in iNKT cell programs and promising results in gastric cancer trials.
Financially, the company ended the year with a cash balance of $3.4 million and reported a net loss of $22.5 million.
Analysts raised questions on enrollment, patient demand, financial strategies, and plans for engineered iNKT cell efforts.
Exploration of iNKT cells in new disorders and combination trials presents growth opportunities for MiNK Therapeutics.

MiNK Therapeutics reports progress in Q1 2024 earnings call

MiNK Therapeutics demonstrated progress in financials and program advancements in Q1 2024, with a focus on iNKT cell platform development.
While facing challenges in managing expenses and achieving profitability, the company's innovative therapies like MiNK-215 and agenT-797 show promise.
The ongoing trials and upcoming presentations offer opportunities for growth and partnerships, positioning MiNK Therapeutics for future success.

MiNK Therapeutics reports progress in iNKT cell therapy programs

MiNK Therapeutics (INKT) is making notable strides in advancing their iNKT cell therapy programs for various medical conditions, showcasing promising clinical results and strategic collaborations.
The company's commitment to innovation, diversification of their pipeline, and proactive approach to funding and partnerships position them well for future growth and success.
While facing regulatory and operational challenges, MiNK has opportunities to leverage their expertise and resources to drive therapy development, expand indications, and enhance treatment efficacy.

MiNK Therapeutics reports progress in iNKT therapy, financial stability

MiNK Therapeutics demonstrated strong performance in advancing their iNKT cell therapy platform and achieving positive clinical outcomes in Q3 2024.
The company's strengths include strategic additions to the Board of Directors, promising preclinical data, and a robust pipeline of potential therapies.
Challenges in trial management, defining endpoints, and financial sustainability need to be addressed, while opportunities exist in partnerships, market expansion, and operational optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the publication of a case report in Oncogene from its phase 1/2 study in patients with advanced solid tumors where one infusion of agenT-797 in gastric cancer refractory to anti-PD1 led to a durable confirmed partial response, highlighting the unique potential of iNKT cells to overcome resistance to immune checkpoint inhibitors (ICIs).

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

SAN DIEGO and NEW YORK and SINGAPORE, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ImmunoScape , a biotechnology company focused on the discovery and development of next-generation T cell receptor (TCR)-based therapeutics, and MiNK Therapeutics , Inc (Nasdaq: INKT), a clinical stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell targeting therapies, today announced a collaboration agreement to discover and develop next-generation TCR therapies against novel targets in solid tumors. The combined efforts of both companies aim to accelerate the development of TCR-based therapies against novel targets in T cells, iNKT cells, and other modalities, potentially offering new therapeutic approaches for diverse cancer indications.

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the third quarter 2023. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and to provide a corporate update.

MiNK Therapeutics Reports Third Quarter 2023 Results

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today presented new agenT-797 data in solid tumor cancers at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting.

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its third quarter 2023 financial results via press release before the market opens on Thursday, Nov. 9, 2023.

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to unveil updated clinical and translational data, along with insights on agenT-797's distinct mechanism of action in solid tumors. A poster will be presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting on November 1-5, 2023.

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer and President, will participate in the following upcoming investor conferences:

MiNK Therapeutics to Participate in September Investor Conferences

-  Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center

MiNK Therapeutics Reports Second Quarter 2023 Results

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its second quarter 2023 financial results via press release before the market opens on Thursday, Aug. 10.

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

NEW YORK, May 22, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data from its allo-iNKTs (agenT-797) in COVID-19 associated Acute Respiratory Distress Syndrome (CARDS) at the American Thoracic Society (ATS) International Conference in Washington D.C.

MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference

NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today presented preclinical data demonstrating the potential of its novel FAP-CAR-iNKT candidate, MiNK-215, at the American Society of Gene and Cell Therapy (ASGCT) annual meeting.

MiNK's Novel FAP-CAR-iNKT Presented at ASGCT

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Zack Armen – Head-Investor Relations Jennifer Buell – President and Chief Executive Officer Marc Van Dijk – Chief Scientific Officer Christine Klaskin – Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar – H.C. Wainwright Jack Allen – Baird Matthew Phipps – William Blair Operator Ladies and gentlemen, thank you for standing by.

MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today provided a corporate update and reported financial results for the first quarter 2023.

MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2023 financial results before the market opens on Thursday, May 11, 2023. Members of the MiNK leadership team will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results

NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, presented data at the American Association of Cancer Research (AACR) annual meeting, demonstrating the clinical benefit of allo-iNKTs, agenT-797, alone and in combination with anti-PD-1 in patients with refractory non-small cell lung cancer (NSCLC), testicular, and gastric cancers.

MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting

After losing some value lately, a hammer chart pattern has been formed for MiNK Therapeutics, Inc. (INKT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

MiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

MiNK Therapeutics, Inc. (INKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

MiNK Therapeutics, Inc. (INKT) Upgraded to Buy: What Does It Mean for the Stock?

AgenT-797 data presented at SITC in November was encouraging. More AgenT-797 cancer data expected at AACR on April 18.

MiNK Therapeutics: iNKT Therapy Data Should Drive Stock Price Up

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q4 2022 Results Conference Call March 21, 2023 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations at MiNK Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Kalpit Patel - B.

MiNK Therapeutics, Inc. (INKT) Q4 2022 Earnings Call Transcript

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the fourth quarter and full year 2022.

MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors

MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and full year 2022 financial results before the market opens on Tuesday, March 21, 2023. Members of the MiNK leadership team will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the HC Wainwright Cell Therapy Virtual Conference on February 28th, at 9:00 AM ET.

MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET.

News for MiNK Therapeutics Stock (INKT)